MGI Tech Co., Ltd. announced the opening of its new European headquarters in Berlin, Germany to support the life science community across the region. The new facility, conveniently located near the Berlin Brandenburg Airport and open to external visits, features MGI's latest products and technologies. The space spans over 600 square meters and features the company's very own Customer Experience Center (CEC) and advanced labs, with plans for further expansion.

It will also be home to prototypes of upcoming MGI products for early access and testing by European partners and collaborators. Equipped with MGI's full product portfolio, the CEC within the new Berlin headquarters serves as a dedicated gateway for researchers and scientists in the region to learn about and experience the company's cutting-edge life science innovation. Through tailored trainings, demos, and hands-on workflow, visitors can explore the full possibilities of creating their own innovative multi-omics tools based on the proprietary DNBSEQ??

technology. The inaugurate initiative launched at the CEC opening is a G400 Developer Program to support researchers in Europe with the development and implementation of customized workflows for spatialcriptomic, multiplex immunofluorescence (mIF) and other multi-omics analysis. Furthermore, the facility has been configured with DNA sequencing, Cell Omics and Spatial Omics capabilities, positioned to support novel application and project development for MGI customers and collaborators.

Following an exceptional start of the year, MGI continues to expand its reach and strives to better serve the life science sector through various partnerships across the region. Notably, in February, the company entered a collaboration agreement with MetaGenoPolis in France, to equip the organization with MGI's DNBSEQ-T7 ultra-high throughput sequencer for the "Le French Gut" project and other research under the Million Microbiomes from humans Project (MMHP). In March, MGI reached a milestone partnership with Eurofins Genomics Europe Genotyping A/S for the first corporate order of the revolutionary DNBSEQ-T20x2 ultra-high throughput sequencer in Europe, paving the way for significant advances in precision health initiatives across the continent.

More recently, the company showcased life science excellence with its extensive offering of lab automation and sequencing products at ECCMID 2024 and announced a technical assessment of the ABL DeepChek®? assays by leading diagnostic and medical software company, ABL Diagnostics, on its DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of the DeepChek®? assay will also be performed on the newly launched DNBSEQ-E25.